Use of Pyrvinium to Reverse Stomach Precancerous Conditions

Participants will receive placebo by mouth once each day for a total of 14 days.

Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.

Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.

Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.

Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.